breaking down the costs of biogen's billion-dollar alzheimer's drug
Published 3 years ago • 3.2K plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
5:04
this analyst breaks down the bull case for biogen's alzheimer's drug
-
1:48
biogen reopens following fda approval of company's alzheimer drug
-
4:32
fda's historic approval of biogen's alzheimer's drug
-
3:40
here's what the fda's endorsement of the alzheimer's drug leqembi means for biogen
-
2:56
cautious on biogen's alzheimer’s drug due to uncertainty around cost, reimbursement, access: wedbush
-
5:56
sofi's liz young thomas says it's time to trim some gains in large caps
-
3:01
potential breakthrough: new treatment for alzheimer's
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
1:53
fda approves biogen alzheimer's drug, first new therapy for the disease in nearly two decades
-
2:41
analyst on what biogen's alzheimer's drug means for the company
-
3:49
biogen ceo on fda approval for its alzheimer's drug
-
5:04
what biogen halted its alzheimer's drug trial means for biotech investors
-
16:02
what’s the controversy behind biogen’s alzheimer’s drug?
-
1:07
fda approves biogen's alzheimer's drug
-
2:56
biogen shares spike after fda approves alzheimer's drug
-
3:07
cement companies are transforming the $410 billion industry with carbon-free cement
-
2:58
evidence to approve biogen's alzheimer's drug was not 'sufficient': penn's dr. jason karlawi
-
1:18
biogen ceo michel vounatsos to step down following troubled alzheimer's drug launch
-
3:45
cramer: biogen's alzheimer's treatment would be 'the biggest drug ever'
-
4:19
why this analyst remains a 'skeptic' on biogen's new alzheimer's drug
-
1:31
alzheimer's drug decision day: fda to decide on biogen and eisai treatments
-
1:50
jim cramer: there will be push back on biogen's alzheimer's drug price